mfn-ext-nq

• 22 May, 2026
  Spago Nanomedical beslutar om en företrädesemission om cirka 16 MSEK
• 22 May, 2026
  Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
• 18 May, 2026
  Spago Nanomedical presents Tumorad® clinical data at the international ANZSNM 2026 conference
• 18 May, 2026
  Spago Nanomedical presenterar kliniska data för Tumorad® vid den internationella ANZSNM-konferensen 2026
• 6 May, 2026
  Spago Nanomedical’s phase I/IIa study Tumorad-01 meets a primary endpoint and provides further visible tumor uptake
• 6 May, 2026
  Spago Nanomedicals fas I/IIa-studie Tumorad-01 uppnår ett primärt effektmått och uppvisar ytterligare tydligt tumörupptag
• 24 Mar, 2026
  Spago Nanomedicals abstract om Tumorad® accepterat för presentation på radiofarma-konferens
• 24 Mar, 2026
  Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference
• 17 Mar, 2026
  Spago Nanomedical fortsätter rekryteringen i fas I/IIa-studien Tumorad-01 efter positiv DMC-rekommendation
• 17 Mar, 2026
  Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation